Ho Y. Lim

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 07, 2026

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 23, 2026

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 23, 2026

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 23, 2026

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Journal: Liver cancer

Published: December 05, 2025

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Journal: Mayo Clinic proceedings

Published: November 12, 2025

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study.

Journal: Gut and liver

Published: October 29, 2025

Expert-involved continuous renal replacement therapy device development: addressing user needs through human factors engineering.

Journal: Expert review of medical devices

Published: September 16, 2025

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.

Journal: Cancer research and treatment

Published: August 04, 2025

Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.

Journal: JHEP reports : innovation in hepatology

Published: July 27, 2025

Increased risk of young-onset pancreatic cancer among adults aged 20-39 years with overweight or obesity, but not underweight: A nationwide cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 18, 2025

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Regorafenib use in patients with unresectable hepatocellular carcinoma: analyses of subgroups of special interest in the observational REFINE study.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

A phase Ib/2a study of fostrox in combination with lenvatinib as second line therapy in patients with advanced hepatocellular carcinoma.

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

A Phase Ib/IIa Study of Fostrox in Combination with Lenvatinib as Second-line Therapy in Patients with Advanced Hepatocellular Carcinoma.

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

Threshold Dose-Response Association Between Alcohol Consumption and Risk of Young-Onset Pancreatic Cancer: A Nationwide Korean Cohort Study of Young Adults Age 20-39 Years.

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study.

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Parity and Risk of Pancreatic Cancer Among Premenopausal Women: A Nationwide Cohort Study.

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study.

Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study.

Expert-involved continuous renal replacement therapy device development: addressing user needs through human factors engineering.

Expert-involved continuous renal replacement therapy device development: addressing user needs through human factors engineering.

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.

Phase 1 Study of IMC-002, a Next-Generation Anti-CD47 Antibody, in Advanced Solid Tumors.

Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.

Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.

Increased risk of young-onset pancreatic cancer among adults aged 20-39 years with overweight or obesity, but not underweight: A nationwide cohort study.

Increased risk of young-onset pancreatic cancer among adults aged 20-39 years with overweight or obesity, but not underweight: A nationwide cohort study.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab.